普罗布考联合不同他汀类药物对脑梗死合并动脉硬化的治疗效果及低密度脂蛋白影响  

The therapeutic effect of probucol combined with different statins on cerebral infarction complicated with arteriosclerosis and its impact on low-density lipoprotein

作　　者：惠佩 牛庆东[1] 戴崇亮 刘乐 Hui Pei;Niu Qingdong;Dai Chongliang;Liu Le(Xi'an Aerospace General Hospital,Xi'an,Shaanxi 710100,China)

机构地区：[1]西安航天总医院,陕西西安710100

出　　处：《首都食品与医药》2025年第3期57-60,共4页Capital Food Medicine

摘　　要：目的探讨普罗布考联合不同他汀类药物对脑梗死合并动脉硬化的治疗效果及低密度脂蛋白(LDL-C)的影响.方法回顾性选择我院近2年治疗的90例脑梗死合并动脉硬化患者分为三组,即常规组、瑞舒伐他汀组、阿托伐他汀组,每组各30例.常规组采取改善循环、神经保护、抗血小板聚集等基础治疗,瑞舒伐他汀组在常规组基础上增加普罗布考联合瑞舒伐他汀治疗,阿托伐他汀组在常规组基础上增加普罗布考联合阿托伐他汀治疗,三组均连续治疗6个月.对比三组治疗前后LDL-C、氧化修饰的低密度脂蛋白(ox-LDL)及ox-LDL抗体水平,对比动脉相关指标、炎性因子相关指标水平及不良反应情况.结果治疗后,瑞舒伐他汀组LDL-C水平低于常规组与阿托伐他汀组,阿托伐他汀组低于常规组(P<0.05),瑞舒伐他汀组与阿托伐他汀组ox-LDL、ox-LDL抗体对比,无明显差异(P>0.05),但瑞舒伐他汀组与阿托伐他汀组均低于常规组(P<0.05);治疗后,瑞舒伐他汀组最大斑块体积指数、平均斑块数量、最大斑块长轴、双侧颈动脉内膜厚度(IMT)低于阿托伐他汀组与常规组,阿托伐他汀组低于常规组(P<0.05);治疗后,瑞舒伐他汀组肿瘤坏死因子-α(TNF-α)、白细胞介素-8(IL-8)、基质金属蛋白酶-9(MMP-9)低于阿托伐他汀组与常规组,阿托伐他汀组低于常规组(P<0.05);三组不良反应发生率对比,无明显差异(P>0.05).结论针对脑梗死合并动脉硬化患者在常规治疗基础上增加普罗布考联合他汀类药物治疗,可降低其LDL-C、ox-LDL水平,同时可逆转斑块,减轻机体炎症因子水平,安全性较高,且瑞舒伐他汀效果优于阿托伐他汀.Objective To investigate the therapeutic effect of probucol combined with different statins on cerebral infarction complicated with arteriosclerosis and the impact on low-density lipoprotein.Methods Retrospectively,90 patients with cerebral infarction and arteriosclerosis admitted in our hospital in the past 2 years were divided into 3 groups,the conventional group,the rosuvastatin group,and the atorvastatin group,with 30 patients in each group.In the conventional group,basic treatments such as improving circulation,neuroprotection and anti-platelet aggregation.The rosuvastatin group received additional treatment with probucol combined with rosuvastatin on the basis of the conventional group,while the atorvastatin group received additional treatment with probucol combined with atorvastatin.All three groups were treated continuously for 6 months.Compare the levels of LDL-C,ox-LDL,and ox-LDL antibodies before and after treatment in three groups of patients,compare the levels of arterial related indicators,inflammatory factor related indicators,incidence of adverse reactions.Results After treatment,the LDL-C levels in the rosuvastatin group were lower than those in the conventional group and the atorvastatin group,and the atorvastatin group was lower than the conventional group(P<0.05).There was no significant difference in ox-LDL and ox-LDL antibodies between the rosuvastatin group and the atorvastatin group(P>0.05),but both the rosuvastatin group and the atorvastatin group were lower than the conventional group(P<0.05);after treatment,the maximum plaque volume index,average number of plaques,maximum long axis of plaques,and bilateral carotid artery IMT in the rosuvastatin group were lower than those in the atorvastatin group and the conventional group,and the atorvastatin group was lower than the conventional group(P<0.05);in the rosuvastatin group,the TNF-α,IL-8,MMP-9 were lower than that in the atorvastatin group and the conventional group,and the atorvastatin group was lower than the conventional group(P<0.05)

关 键 词：普罗布考 瑞舒伐他汀 阿托伐他汀 脑梗死 动脉硬化 低密度脂蛋白 

分 类 号：R743.33[医药卫生—神经病学与精神病学]